Press Releases

BiondVax Pharmaceuticals Ltd. selects Cytovance® Biologics Inc. for the manufacturing of M-001 the universal flu…

Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE, NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.

Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc.

Cytovance® Biologics, Inc., announced today that they have entered into a definitive agreement by which Hepalink USA Inc. will acquire Cytovance® Biologics Inc., a leading biopharmaceutical contract development manufacturing company.

Cytovance® Biologics Inc. Announces Development & Manufacturing Deal With NeuroFx

Cytovance® Biologics, Inc., a leading full-service contract development and manufacturer of mammalian and microbial biologics, announces that it has teamed up with NeuroFx to develop and manufacture stem cell derived, cell-free therapy for neurological conditions.

Cytovance® Biologics Inc., Honored at 2015 CMO Leadership Awards

Oklahoma City, OK - Cytovance® Biologics Inc., a leader in the manufacturing of mammalian and microbial biopharmaceuticals announced it has received four CMO Leadership Awards for 2015

Cytovance® Biologics’ Jesse McCool, Ph.D., to present at 2015 BioInnovation Summit in London, UK

Oklahoma City, OK-Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing company is gearing up for The BioInnovation Summit in London, UK February 10-11, 2015. Jesse McCool, Ph.D., will present on one of Cytovance’s open innovation projects, the Keystone Expression System™

Cytovance® Biologics, Inc. Announces New Hire in R&D

Cytovance Biologics, Inc. is pleased to announce the appointment of Seth Fisher as Director of Purification Development in the R&D Services group.